Open AccessIncreased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
Author(s) -
Li-Chun Lu,
YiHsuan Lee,
ChungCheng Chang,
Chia–Tung Shun,
ChihYeu Fang,
YuYun Shao,
Tsung-Hao Liu,
AnnLii Cheng,
ChihHung Hsu
Publication year - 2018
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 2235-1795
pISSN - 1664-5553
DOI - 10.1159/000489021
Subject(s) - sorafenib , hepatocellular carcinoma , immunohistochemistry , medicine , immune system , pd l1 , oncology , cancer research , pathology , immunotherapy , immunology , cancer
Programmed death-ligand 1 (PD-L1) expression in the tumor microenvironment (TME) has been reported to be related to prognosis in patients with hepatocellular carcinoma (HCC) after hepatectomy. The impact of sorafenib on PD-L1 expression in the TME of advanced HCC is unclear.